Megestrol acetate for treatment of endometriosis.
Between 1977-1989, 29 women with symptomatic endometriosis were treated with megestrol acetate by the Johns Hopkins Division of Reproductive Endocrinology. All had previously received one or more alternative medical treatments for endometriosis, in each case discontinued because of poor response or development of unacceptable side effects. Treatment consisted of a daily dose of 40 mg megestrol acetate orally for up to 24 months. Disease-related symptoms (dysmenorrhea, noncyclic pelvic pain, and dyspareunia) were relieved in 86% of the subjects treated with an adequate course of therapy. Side effects were fairly well tolerated, although eight women discontinued treatment within 2 months and two others stopped the drug by 4 months. These preliminary findings suggest that megestrol acetate may be an effective treatment for patients with endometriosis, even those who have been unresponsive to other modes of therapy.
Schlaff
W D
WD
Department of Gynecology and Obstetrics, Johns Hopkins Medical Institutions, Baltimore.
Dugoff
L
L
Damewood
M D
MD
Rock
J A
JA
D000328:Adult; D004715:Endometriosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008535:Megestrol / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D019290:Megestrol Acetate; D008875:Middle Aged; D010386:Pelvic Neoplasms / Q000188:drug therapy*
D008535:Megestrol; D019290:Megestrol Acetate